/
Markets
Crypto
News
Forecasts
Forex Brokers
Calendars
Macro Data
About us
Commodity Prices
Currency Rates
Cryptocurrency Prices
Global Market Indices
Stock Prices
ETF Prices
Cryptocurrency Prices
Crypto Exchanges
Crypto Wallets
Cryptocurrency News
Cryptocurrency Forecasts
Commodity News
Forex News
Crypto News
Stock Market News
Economic News
Opinions
Broker News
Commodities
Forex
Crypto
Indices
Natural Gas Forecasts
Gold Forecasts
WTI Crude Oil Forecasts
S&P 500 Forecasts
Forex Brokers Reviews
Best Brokers Guides
Compare Forex Brokers
Best Forex Brokers
Best Forex Platforms
Best MT4 Brokers
Best for Trading Gold
Best Brokers in Australia
Best Brokers for Beginners
Best Brokers in UK
Brokers Promotions
Stock Brokers
Economic Calendar
Earnings Calendar
Splits Calendar
Dividends Calendar
Holiday Calendar
IPO Calendar
Stock Screener
Currency Converter
Global Macro indicators
Sovereign Credit Ratings
Global Major Indicators
Interest Rates
United States Indicators
China Indicators
Australia Indicators
Euro Area Indicators
About us
Contact Us
Terms Of Use
Become A Contributer
EUR/USD
-0.15%
Natural Gas
+2.22%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
+0.11%
VIX
N/A
Economic Calendar
EUR/USD
-0.15%
Natural Gas
+2.22%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
+0.11%
VIX
N/A
Economic Calendar
BTC
N/A
ETH
N/A
XRP
N/A
ADA
N/A
SOL
N/A
Review
Review
Review
Will the PCE Report Derail the Fed’s Anticipated Rate Cut Plans?
21 minutes ago
The Market News Today: Upcoming PCE Report to Influence Fed’s Rate Decisions
about 2 hours ago
US GDP for Previous Quarter Adjusted Upward to a Robust Annual 3.4%
about 21 hours ago
The Market News Today: US GDP Forecast at 3.2%, Eyes on Fed and Market Response
1 day ago
German Retail Sales Tumble 1.9% in February Driving ECB Rate Cut Bets
1 day ago
Georgia’s Credit Outlook Constrained By Geopolitical Sensitivities, Institutional Risks
2 days ago
Nasdaq Index, Dow Jones, S&P 500 News: Are Bullish Trends Set to Continue?
24 minutes ago
Gold Prices Forecast: Unstoppable Rise Enters New Territory – What’s Next?
about 1 hour ago
Crude Oil News Today: Rising Brent Prices Indicate Bullish Short-term Outlook
about 2 hours ago
Bitcoin Fails To Surpass $71k This Week
about 3 hours ago
EUR/USD, GBP/USD, DXY Price Forecast: Good Friday Eyes on Fed Talks
about 5 hours ago
Gold, Silver, Copper Daily Forecast: Eyes on FED; More Buying Ahead?
about 6 hours ago
Quick Links
:
Forecasts
Economic Calendar
Commodities
Trade Now
ad
ad
Advertisement
Advertisement
home
stocks
ALNY
profile
Alnylam Pharmaceuticals Inc
Follow
ALNY
(
Nasdaq - US
)
Closed
149.37
-5.02 (-3.25%)
in
:
usd
•
As of: Mar 28, 2024 15:59
UTC -4
Open
154.40
High
154.40
Low
149.36
Overview
News & Analysis
Profile
Financials
Advanced Chart
History
Earnings
About
Alnylam Pharmaceuticals Inc
CEO
Yvonne L. Greenstreet
Headquarters
675 west kendall street, henri a. termeer square
cambridge, ma 02142, united states
Auditor
PricewaterhouseCoopers LLP
Employees
2,100
Share Holders
24
Website
www.alnylam.com
Industry
pharmaceuticals major
Sector
health technology
Company Overview
Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic disease and hepatic infectious disease. The company's lead drug-Onpattro received regulatory approvals in the United States and Europe for the treatment of hereditary transthyretin-mediated amyloidosis in adults. The FDA approved Givlaari for acute hepatic porphyria. The FDA approved Oxlumo injection for subcutaneous use, for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients. Moreover, the company is evaluating inclisiran for hypercholesterolemia in partnership with The Medicines Company acquired by Novartis. The FDA approved Leqvio to reduce low-density lipoprotein cholesterol with two doses a year..
Alnylam Pharmaceuticals Inc
Statistics
Valuation Measures
Market Capitalization
2
18.81B
Enterprise Value
19.02B
Enterprise Value/EBITDA
(ttm)
-102.74
Price to Earnings Ratio
(ttm)
N/A
Price to Book
(mrq)
N/A
Price to Sales
(ttm)
10.47
Price to Cash
(ytd)
N/A
Profitability
Gross Margin
(ttm)
81.32%
Operating Margin
(ttm)
-24.08%
Profit Margin
(ttm)
-38.20%
Return on Equity
(ttm)
N/A
Return on Invested Capital
(ttm)
-68.07%
Return on Assets
(ttm)
-12.18%
Income Statement
Revenue
(ttm)
1.83B
Revenue Per Share
(ttm)
14.52
Gross Profit
(ttm)
1.52B
EBITDA
(ttm)
3
-185.14M
Net Income Avi to Common
(ttm)
-440.24M
Diluted EPS
(ttm)
-3.56
Share Statistics
Beta (5Y Monthly)
0.39
52-Week Change
-23.76%
S&P500 52-Week Change
30.45%
S&P500 Member
No
Stock Optionable
Yes
Total Shares Outstanding
1
125.95M
Dividend Yield
0.00%
Float
4
124.18M
%
Held by Insiders
1.40%
%
Held by Institutions
92.97%
Balance Sheet
Total Cash
(mrq)
2.44B
Total Cash Per Share
(mrq)
19.37
Total Debt
(mrq)
1.02B
Total Debt/Equity
(mrq)
-462.63%
Current Ratio
(mrq)
3.08%
Quick Ratio
(mrq)
2.99%
Book Value Per Share
(mrq)
-1.75
Cash Flow
Operating Cash Flow Per Share
(ytd)
0.83
Free Cash Flow
(ytd)
41.95M
Table Key
mrq
=
Most Recent Quarter
ttm
=
Trailing Twelve Months
ytd
=
Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.
1
Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2
Market Cap is calculated using total shares outstanding and the most recent share price.
3
EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4
The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Sponsored
Sponsored
This Section / Page contains links to the 3rd party websites of our top partners from whom we may receive compensation.
Trade With A Regulated Broker